
-
Gill launches India captaincy reign in style with hundred against England
-
Mexico's Sheinbaum claims drop in homicides, experts dubious
-
Russia might try to take Ukrainian city of Sumy, Putin says
-
Zverev battles in Halle, faces Medvedev in semis
-
Tennis star Sinner releases duet with Italian tenor Bocelli
-
Giorgio Armani to miss Milan Fashion Week shows
-
Armenia PM in talks with Erdogan on 'historic' Turkey visit
-
Royal Ascot is 'heaven on earth' for shock winner Cercene's trainer
-
Iran's nuclear programme: from its origins to today's dispute
-
Draper digs deep to reach Queen's semi-finals for first time
-
Afghan-born Nadia Nadim returns to Danish team for Euros
-
NATO scrambles to overcome Spain block on summit spending deal
-
Putin says recession in Russia 'must not be allowed to happen'
-
Ton-up Jaiswal makes England toil in first Test as India take control
-
NBA star Durant takes minority PSG stake
-
US enters first major heat wave of 2025
-
Macron says Europe must become 'space power' again
-
Big-name porn sites back online in France after age check row
-
Zverev battles into Halle semis, joined by Medvedev
-
Romania names pro-EU PM after months of instability
-
Indonesia President denies G7 snub in Russia visit
-
European powers meet Iran in Geneva as war with Israel rages
-
Staff shortages bite as Greeks shun low-paid tourism jobs
-
EU plans to scrap anti-greenwashing rules after pushback
-
Iranian foreign minister says Israel attack 'betrayal' of diplomacy with US
-
Oil drops, stocks climb as Trump delays Iran move
-
UK MPs vote in favour of assisted dying law in historic step
-
Bangladesh's lead over Sri Lanka nears 200 in first Test
-
Dutch footballer Promes extradited over cocaine smuggling case
-
World Bank and IMF climate snub 'worrying': COP29 presidency
-
Liverpool agree deal for Bournemouth's Kerkez: reports
-
UK probes Amazon over suspected late payments to food suppliers
-
Sinner says early Halle exit gives him more time to prepare for Wimbledon
-
England strike back against India in first Test
-
Netanyahu's other battle: swinging Trump and US behind Iran war
-
French champagne makers face prison in human trafficking trial
-
Oil drops, European stocks climb as Trump delays Iran move
-
Kiwi sailing legend Burling joins Italy's America's Cup team
-
US singer Chris Brown pleads not guilty in UK assault case
-
UK MPs debate assisted dying law ahead of key vote
-
Second woman accuses French senator of drugging her
-
Russian government, central bank spar over economic downturn
-
Thai PM meets army commander in attempt to defuse political crisis
-
More microplastics in glass bottles than plastic: study
-
Top Iran, EU diplomats to hold nuclear talks
-
Armenia PM arrives in Turkey for 'historic' visit
-
Salah among nominees for PFA Player of the Year award
-
EU bars Chinese firms from major state medical equipment contracts
-
Three-time world champion figure skater Sakamoto to retire
-
Crude sinks as Trump delays decision on Iran strike

Drew Weissman, Nobel-winning mRNA pioneer
Drew Weissman's decades of research into mRNA technology paved the way for Covid-19 vaccines, finally earning a Nobel prize for the physician-scientist.
The 64-year-old University of Pennsylvania immunologist, who won the Nobel Medicine Prize along with long-time collaborator Katalin Kariko on Monday, is far from done.
His next quests include, among others, developing a vaccine against all future coronaviruses.
"There have been three (coronavirus) pandemics or epidemics in the past 20 years," Weissman told AFP recently, referring to the original SARS virus, MERS and Covid-19.
"You have to assume there's going to be more, and our idea was that we could wait for the next coronavirus epidemic or pandemic, and then spend a year and a half making a vaccine. Or we could make one now."
- Twin breakthroughs-
The world is now aware of the elegance of the mRNA (messenger ribonucleic acid) vaccines, that deliver genetic instructions to cells telling them to recreate the spike protein of the coronavirus, in order to trigger effective antibodies when they encounter the real thing.
But back when Weissman teamed up with Kariko in the 1990s, the research was considered a scientific dead-end, and working with DNA was considered a more promising avenue.
"We started working together in 1998, and that was without much funding and without much in the way of publications," he said.
In 2005, the pair found a way to alter synthetic RNA to stop it from causing a massive inflammatory response found in animal experiments.
"Just before our paper was published, I said 'Our phones are going to ring off the hook,'" he recalls.
"We sat there staring at our phones for five years, and they never rang!"
With a second big breakthrough in 2015, they found a new way to deliver the particles safely and effectively to their target cells, using a fatty coating called "lipid nanoparticles."
Both developments are part of the Pfizer and Moderna Covid-19 vaccines today.
- Helping people -
Weissman grew up in Lexington, Massachusetts.
His father and mother, both since retired, were an engineer and dental hygienist, respectively.
"When I was five years old, I was diagnosed as a type-one diabetic, and back then it was testing urine and taking insulin shots a few times a day," he recalled, and this motivated him to pursue science.
He was educated at Brandeis University and completed an MD-Phd program in immunology at Boston University.
As a young fellow at the National Institutes of Health, he worked for several years in Anthony Fauci's lab on HIV research, before finally arriving at his long-time home Penn.
Weissman was a practicing doctor until a few years ago, and says it brings him great joy that his invention has helped save millions of lives.
"I'm a clinician scientist, my dream since starting college and medical school was to make something that helps people. I think I can say that I've done that. So I am incredibly happy," he said.
Beyond vaccines, mRNA technology is also being heralded for its potential across medicine.
Weissman's team is working on using RNA to develop a single-injection gene therapy to overcome the defect that causes sickle cell anemia, a genetic blood disease that 200,000 babies are born with in Africa every year.
Significant technical challenges remain to ensure the treatment is able to correctly edit genes and is safe, but the researchers are hopeful.
Bone marrow transplant, an expensive treatment with serious risks, is currently the only cure.
S.Gantenbein--VB